Blue Sail Medical has completed the acquisition of Swiss based company NVT AG. The closure of the deal was publicly announced on the Shenzhen Stock Exchange on the 9 June 2020, and a press release from Blue Sail Medical says it will leverage the capabilities and experience in interventional cardiology of its subsidiary, Biosensors International Group.
The company statement says the deal brings together NVT’s expertise in innovative transcatheter aortic valve implantation technology, and Biosensors’ solid track record in interventional cardiology.
“The closing of this transaction represents a new and exciting era for the company, and specifically the new structural heart business unit, as we seek to continue improve patients’ lives through pioneering medical technology. It broadens the company’s assets and will provide strategic growth opportunities, particularly in the transcatheter aortic valve replacement market. Together, we look forward to leveraging and further accelerating Biosensor’s drive to deliver the greatest possible patient outcomes,” comments Brian Fan Yang, Blue Sail executive committee member and CEO Biosensors International Group.
The press release states that the ALLEGRA transcatheter aortic valve implantation system stemmed from NVT’s strong research and development pipeline and manufacturing capabilities based in Germany. The company developed and launched the ALLEGRA™ TAVI system, which received CE mark in 2017. It describes it as a self-expanding supra-annular transcatheter aortic valve, which presents unique design features and similar event rates compared to contemporary devices.